Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CKD-337 in Healthy Male Volunteers
NCT02651753Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jan 2016
- Primary completion
- Mar 2016
01
Overview
Phase 1, randomised, open-label trial of CKD-337 in dyslipidemia (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Atorvastatin Area Under the Curve from time zero to last quantifiable concentration, Atorvastatin Maximum Plasma Concentration and 2 more. Started Jan 2016; status: completed.
02
Drugs
CKD-337
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT02651753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02651753.